164 related articles for article (PubMed ID: 36222846)
21. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
[TBL] [Abstract][Full Text] [Related]
23.
Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
[TBL] [Abstract][Full Text] [Related]
24. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
[TBL] [Abstract][Full Text] [Related]
25.
Emmanuel N; Li H; Chen J; Zhang Y
Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
27. Genomic landscape of chemical-induced lung tumors under Nrf2 different expression levels.
Satoh H; Arai Y; Furukawa E; Moriguchi T; Hama N; Urushidate T; Totoki Y; Kato M; Ohe Y; Yamamoto M; Shibata T
Carcinogenesis; 2022 Aug; 43(7):613-623. PubMed ID: 35561328
[TBL] [Abstract][Full Text] [Related]
28. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
[TBL] [Abstract][Full Text] [Related]
29. Is clinical radiosensitivity a complex genetically controlled event?
Filippi AR; Franco P; Ricardi U
Tumori; 2006; 92(2):87-91. PubMed ID: 16724685
[TBL] [Abstract][Full Text] [Related]
30. A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ; Ooi A
Sci Rep; 2018 Aug; 8(1):12846. PubMed ID: 30150714
[TBL] [Abstract][Full Text] [Related]
31. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
Hellyer JA; Padda SK; Diehn M; Wakelee HA
J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of hormone-dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms.
Almeida M; Soares M; Ramalhinho AC; Moutinho JF; Breitenfeld L
Mol Biol Rep; 2019 Jun; 46(3):3213-3224. PubMed ID: 30941643
[TBL] [Abstract][Full Text] [Related]
33. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
34. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
[TBL] [Abstract][Full Text] [Related]
35. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
36.
Noel S; Lee SA; Sadasivam M; Hamad ARA; Rabb H
J Immunol; 2018 Mar; 200(5):1929-1936. PubMed ID: 29352001
[TBL] [Abstract][Full Text] [Related]
37. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
Goldstein LD; Lee J; Gnad F; Klijn C; Schaub A; Reeder J; Daemen A; Bakalarski CE; Holcomb T; Shames DS; Hartmaier RJ; Chmielecki J; Seshagiri S; Gentleman R; Stokoe D
Cell Rep; 2016 Sep; 16(10):2605-2617. PubMed ID: 27568559
[TBL] [Abstract][Full Text] [Related]
38. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
39. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
Lister A; Nedjadi T; Kitteringham NR; Campbell F; Costello E; Lloyd B; Copple IM; Williams S; Owen A; Neoptolemos JP; Goldring CE; Park BK
Mol Cancer; 2011 Apr; 10():37. PubMed ID: 21489257
[TBL] [Abstract][Full Text] [Related]
40. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
